Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$537.92
-0.5%
$586.40
$379.39
$678.21
$32.85B0.39326,238 shs252,942 shs
QIAGEN N.V. stock logo
QGEN
QIAGEN
$46.54
0.0%
$43.50
$37.63
$49.30
$10.35B0.671.19 million shs870,336 shs
Seagen Inc. stock logo
SGEN
Seagen
$228.74
$228.74
$123.77
$228.96
$42.93B0.321.48 million shs86 shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$50.13
+1.3%
$49.53
$46.01
$83.62
$7.86B1.381.42 million shs2.16 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
-0.52%-6.44%-6.95%-12.25%+42.32%
QIAGEN N.V. stock logo
QGEN
QIAGEN
-0.09%-0.36%+8.81%+18.29%+9.42%
Seagen Inc. stock logo
SGEN
Seagen
0.00%0.00%0.00%0.00%0.00%
Bio-Techne Corp stock logo
TECH
Bio-Techne
+1.27%-2.74%+1.72%-16.92%-32.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
argenex SE stock logo
ARGX
argenex
4.3905 of 5 stars
4.54.00.00.02.51.72.5
QIAGEN N.V. stock logo
QGEN
QIAGEN
2.948 of 5 stars
1.12.00.84.51.91.71.3
Seagen Inc. stock logo
SGEN
Seagen
N/AN/AN/AN/AN/AN/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
4.8721 of 5 stars
4.23.01.74.22.81.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
3.05
Buy$709.1831.84% Upside
QIAGEN N.V. stock logo
QGEN
QIAGEN
2.22
Hold$47.742.57% Upside
Seagen Inc. stock logo
SGEN
Seagen
0.00
N/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
2.45
Hold$72.0043.63% Upside

Current Analyst Ratings Breakdown

Latest ARGX, SGEN, TECH, and QGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
argenex SE stock logo
ARGX
argenex
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$715.00
6/10/2025
argenex SE stock logo
ARGX
argenex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$720.00
6/5/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
5/30/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$59.00
5/21/2025
argenex SE stock logo
ARGX
argenex
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/14/2025
argenex SE stock logo
ARGX
argenex
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$699.00
5/14/2025
argenex SE stock logo
ARGX
argenex
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/13/2025
argenex SE stock logo
ARGX
argenex
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/13/2025
argenex SE stock logo
ARGX
argenex
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$680.00 ➝ $680.00
5/9/2025
argenex SE stock logo
ARGX
argenex
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$704.00 ➝ $708.00
5/9/2025
argenex SE stock logo
ARGX
argenex
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,100.00 ➝ $1,065.00
(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$2.25B14.58$2.97 per share181.09$90.49 per share5.94
QIAGEN N.V. stock logo
QGEN
QIAGEN
$1.98B5.23$3.21 per share14.52$16.05 per share2.90
Seagen Inc. stock logo
SGEN
Seagen
$2.30B18.66N/AN/A$15.10 per share15.15
Bio-Techne Corp stock logo
TECH
Bio-Techne
$1.16B6.78$2.31 per share21.66$13.13 per share3.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$833.04M$16.2133.1849.580.9740.20%16.15%14.33%7/24/2025 (Estimated)
QIAGEN N.V. stock logo
QGEN
QIAGEN
$83.59M$0.40116.6918.922.374.68%14.61%8.80%7/30/2025 (Estimated)
Seagen Inc. stock logo
SGEN
Seagen
-$610.31M-$4.01N/AN/AN/A-32.61%-28.06%-20.92%N/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$168.10M$0.8261.1325.452.6510.89%13.17%10.17%8/6/2025 (Estimated)

Latest ARGX, SGEN, TECH, and QGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
argenex SE stock logo
ARGX
argenex
$2.32$2.58+$0.26$2.58$748.34 million$1.35 billion
5/7/2025Q1 2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.50$0.55+$0.05$0.41$465.66 million$483.46 million
5/7/2025Q3 2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.51$0.56+$0.05$0.14$317.92 million$316.18 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
QIAGEN N.V. stock logo
QGEN
QIAGEN
N/AN/AN/AN/AN/A
Seagen Inc. stock logo
SGEN
Seagen
N/AN/AN/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.320.64%N/A39.02%N/A

Latest ARGX, SGEN, TECH, and QGEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/19/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
quarterly$0.080.67%5/19/20255/19/20255/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
7.29
6.68
QIAGEN N.V. stock logo
QGEN
QIAGEN
0.40
3.37
2.83
Seagen Inc. stock logo
SGEN
Seagen
N/A
2.67
2.12
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.16
3.71
2.58

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
QIAGEN N.V. stock logo
QGEN
QIAGEN
70.00%
Seagen Inc. stock logo
SGEN
Seagen
84.26%
Bio-Techne Corp stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
QIAGEN N.V. stock logo
QGEN
QIAGEN
9.00%
Seagen Inc. stock logo
SGEN
Seagen
25.90%
Bio-Techne Corp stock logo
TECH
Bio-Techne
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,59961.06 million59.58 millionOptionable
QIAGEN N.V. stock logo
QGEN
QIAGEN
5,765222.29 million202.29 millionOptionable
Seagen Inc. stock logo
SGEN
Seagen
3,256187.70 million139.08 millionOptionable
Bio-Techne Corp stock logo
TECH
Bio-Techne
3,100156.77 million150.65 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
argenex stock logo

argenex NASDAQ:ARGX

$537.92 -2.79 (-0.52%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$553.00 +15.08 (+2.80%)
As of 06/18/2025 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

QIAGEN stock logo

QIAGEN NYSE:QGEN

$46.54 -0.01 (-0.02%)
Closing price 06/18/2025 03:59 PM Eastern
Extended Trading
$46.56 +0.02 (+0.03%)
As of 06/18/2025 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Seagen stock logo

Seagen NASDAQ:SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$50.13 +0.63 (+1.27%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$50.14 +0.02 (+0.03%)
As of 06/18/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.